Longevity Science

Caloric restriction and longevity: the biology behind the oldest intervention

Caloric restriction extends lifespan across more species than any other known intervention. Here is the pathway biology connecting it to mTOR, AMPK, and most of the drugs Geroevidence tracks.

July 26, 2026  ·  8 min read

The klotho protein and aging: what it does and why it's a drug target

Klotho's discovery via a single-gene mouse mutation produced one of the most striking aging phenotypes in mammalian biology. Here is the mechanism behind why it's become a longevity drug target.

July 26, 2026  ·  8 min read

Quercetin as a senolytic: the evidence behind half of D+Q

Quercetin is half of the D+Q senolytic combination and a widely sold standalone supplement. Its own dedicated senolytic evidence, separate from the combination, is thinner than its ubiquity suggests.

July 26, 2026  ·  7 min read

NAD+ IV therapy safety: what human data actually exists

NAD+ IV drips are a fast-growing wellness-clinic offering with almost no published efficacy data — and a safety literature that is thinner than the treatment's popularity would suggest.

July 26, 2026  ·  6 min read

What is a geroprotector? Definition, examples, and current evidence

"Geroprotector" is a scientific term, not a regulatory or marketing one — and that gap is exactly where a lot of longevity-supplement confusion comes from.

July 25, 2026  ·  8 min read

The mTOR pathway and aging: a clinical reference for longevity medicine

mTOR is the central nutrient-sensing hub that rapamycin inhibits. Understanding it is prerequisite to understanding half the longevity pharmacopeia. Here is what the pathway does and why it matters clinically.

July 19, 2026  ·  14 min read

The AMPK pathway and aging: what metformin, exercise, and caloric restriction have in common

AMPK is the energy-sensing kinase activated by metformin, exercise, and caloric restriction. Here is what the pathway does, how interventions activate it, and what the longevity evidence shows.

July 19, 2026  ·  13 min read

Autophagy and longevity medicine: the clinical relevance of cellular recycling

Autophagy — the cellular recycling system — declines with age and is activated by rapamycin, fasting, and exercise. Here is what the evidence shows for interventions that target it.

July 19, 2026  ·  12 min read

Cellular senescence and senolytics: the biology and evidence for clearing aged cells

Senescent cells accumulate with age and drive inflammation through the SASP. Senolytics clear them. Here is what the biology is, what the human evidence shows, and what remains to be established.

July 19, 2026  ·  13 min read

Epigenetic clocks explained: what biological age tests can and can't tell you

Direct-to-consumer biological age tests have become a popular longevity-adjacent product. Here is what the underlying science measures, and what it doesn't yet validate.

June 24, 2026  ·  9 min read

Is longevity medicine legitimate? What the research community actually says

The field spans serious NIH-funded geroscience and unregulated supplement marketing, often using the same vocabulary. Distinguishing them requires looking at specific claims, not the field as a whole.

June 24, 2026  ·  9 min read

The hallmarks of aging explained: a clinical reference

The twelve hallmarks of aging are the biological framework underlying every intervention in the longevity pharmacopeia. What each hallmark is, why it matters clinically, and which interventions target it.

May 7, 2026  ·  16 min read